Realigning incentives for antibiotic innovation
Tracks
Track 1
| Wednesday, October 30, 2024 |
| 2:50 PM - 3:35 PM |
| Plenary Room |
Details
Antimicrobial resistance (AMR) threatens the foundation of modern medicine – antibiotics. Projected to cause more deaths than cancer and cost the global economy USD 100 trillion by 2050, AMR presents both a severe health and economic crisis. As existing antibiotics lose effectiveness, the need for new treatments becomes critical. However, despite the magnitude of this issue, the pipeline for new antibiotics is alarmingly sparse. The World Health Organization (WHO) warns that “innovation is badly lacking”. Solutions are urgently needed.
Join us for an engaging discussion on the pressing AMR crisis and how commercial incentives to develop new antibiotics can be realigned to meet this critical demand.
Speaker
Dr Alan Paul
Executive Country Medical Director
GSK Australia
Panellist
Prof Karin Thursky
Director
National Centre for Antimicrobial Stewardship
Panellist
Dean Whiting
Chief Executive Officer
Pathology Technology Australia
Panellist
